您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Pyrrolidinedithiocarbamate ammonium
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Pyrrolidinedithiocarbamate ammonium
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Pyrrolidinedithiocarbamate ammonium图片
CAS NO:5108-96-3
规格:≥98%
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议
2g电议
5g电议
10g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 164.29
Formula C5H9NS2.H3N
CAS No. 5108-96-3
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO:>35 mg/mL
Water: >35 mg/mL
Ethanol: >35 mg/mL
Solubility (In vivo)
Synonyms Pyrrolidinedithiocarbamate ammonium; Ammonium 1-Pyrrolidinecarbodithioate; PDTC; APDC.
SMILES Code [S-]C(N1CCCC1)=S.[NH4+]
实验参考方法
In Vitro

In vitro activity: Pretreatment of cells with pyrrolidinedithiocarbamate (3-1000 μM) dose-dependently attenuates IL-8 production. Furthermore, pyrrolidinedithiocarbamate (100 μM) suppresses the accumulation of IL-8 mRNA. Pyrrolidinedithiocarbamate inhibits the activation of NF-kB, because pyrrolidinedithiocarbamate suppresses both NF-kB DNA binding and NF-kB-dependent transcriptional activity. NF-kB inhibition with pyrrolidinedithiocarbamate decrease IL-8 production by intestinal epithelial cells.


Kinase Assay:


Cell Assay: The human colon cancer cell line HT-29 is obtained and cells are grown in modified McCoy’s 5A medium supplemented with 10% fetal bovine serum. To study the effect of pyrrolidinedithiocarbamate ammonium on IL-8 production, HT-29 cells in 96-well plates are induced with 20 ng/mL of IL-1β for 18 h. Various concentrations (3-1000 μM) of pyrrolidinedithiocarbamate or its vehicle (culture medium) are added to the cells 30 min prior to IL-1β stimulation. The concentration of IL-8 in the supernatant is determined using solid-phase enzyme-linked immunosorbent assay.

In VivoThe DSS+pyrrolidinedithiocarbamate ammonium-treated groupII exhibits suppression of shortening of intestinal length and reduction of DAI score. Activated NF-κB level and IL-1β and TNF-α levels are significantly lower in DSS+pyrrolidinedithiocarbamate ammonium-treated groupII. These findings suggest that suppression of NF-κB activity by pyrrolidinedithiocarbamate ammonium can delay the healing of mucosal tissue defects (erosions or ulcers) arising from inflammation, but that it can strongly suppress the expression of inf-lammatory cytokines (IL-1β and TNF-α), resulting in significant alleviation of colitis. pyrrolidinedithiocarbamate ammonium is useful for the treatment of ulcerative colitis
Animal model Sprague-Dawley rats
Formulation & Dosage Dissolved in saline; 50, 100, and 200 mg/kg; i.v.
References Pharm Biol. 2014 Nov;52(11):1460-6.